Skip to content

Study · Randomized controlled trial · 2007

8 results

Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study.

Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG

The Journal of clinical endocrinology and metabolism13 Mar 2007Cited by 100 (Europe PMC)

PMID17356043 (opens in a new tab)DOI10.1210/jc.2007-0204 (opens in a new tab)PepBankPUB-17356043
Source linkPubMedAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In short prepubertal children, GH titrated to high IGF-I produced greater linear growth than conventional GH dosing (P < 0.001).

    In plain wordsIn short prepubertal children, GH titrated to high IGF-I increased growth more than conventional GH dosing.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLinear growth with high versus conventional target
    Study

    n: not reported in source

    Comparator
    Conventional GH dose of 40 microg/kg/d
    Analysis
    Primary
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    Height SDS change
    1.6 SDS
    IGF(high)
    Height SDS change
    1 SDS
    conventional

    Source sentences

    Summary
    The changes in HT-SDS were +1.0, +1.1, and +1.6 for conventional, IGF((low)), and IGF((high)), respectively, with IGF((high)) showing significantly greater linear growth response (P < 0.001, compared with the other two groups).
    2 context sentences
    Summary · context
    This was a 2-yr, open-label, randomized, IGF-I concentration-controlled trial.
    Summary · context
    Prepubertal short children [n = 172, mean age 7.53 yr, mean height sd score (HT-SDS) -2.64] with low IGF-I levels (mean IGF-I SDS -3.56) were randomized to receive one of two GH dose-titration arms
  2. 02HumanRandomized controlled trialEfficacy outcome

    In short prepubertal children, GH titrated to high IGF-I produced greater linear growth than low-target GH dosing (P < 0.001).

    In plain wordsIn short prepubertal children, GH titrated to high IGF-I increased growth more than low-target GH dosing.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLinear growth with high versus low IGF-I target
    Study

    n: not reported in source

    Comparator
    GH titrated to low IGF-I target
    Analysis
    Primary
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    Height SDS change
    1.6 SDS
    IGF(high)
    Height SDS change
    1.1 SDS
    IGF(low)

    Source sentences

    Summary
    The changes in HT-SDS were +1.0, +1.1, and +1.6 for conventional, IGF((low)), and IGF((high)), respectively, with IGF((high)) showing significantly greater linear growth response (P < 0.001, compared with the other two groups).
    2 context sentences
    Summary · context
    This was a 2-yr, open-label, randomized, IGF-I concentration-controlled trial.
    Summary · context
    Prepubertal short children [n = 172, mean age 7.53 yr, mean height sd score (HT-SDS) -2.64] with low IGF-I levels (mean IGF-I SDS -3.56) were randomized to receive one of two GH dose-titration arms
  3. 03HumanRandomized controlled trialOther

    In short prepubertal children, the high IGF-I target required GH doses >2.5 times those of the low target, ranging from 20-346 microg/kg/d.

    In plain wordsIn short prepubertal children, the high IGF-I target required more GH than the low target.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseGH dose requirement
    Study

    n: not reported in source

    Comparator
    Low IGF-I target arm
    Outcome group
    Dose Requirements · Pharmacology
    Studied dose
    20-346 microg/kg/d · 2 yearsAs given in this study (human).

    Measurements

    GH dose ratio, IGF(high) versus IGF(low)
    > 2.5 times
    IGF(high) arm versus IGF(low) arm
    GH dose range
    20 to 346 microg/kg/d
    GH doses, highly variable

    Source sentences

    Summary
    The IGF((high)) arm required higher doses (>2.5 times) than the IGF((low)) arm, and these GH doses were highly variable (20-346 microg/kg/d).
    2 context sentences
    Summary · context
    This was a 2-yr, open-label, randomized, IGF-I concentration-controlled trial.
    Summary · context
    Prepubertal short children [n = 172, mean age 7.53 yr, mean height sd score (HT-SDS) -2.64] with low IGF-I levels (mean IGF-I SDS -3.56) were randomized to receive one of two GH dose-titration arms
  4. 04HumanNon-randomized trialEfficacy outcome

    In short prepubertal children, conventional GH dosing increased height SDS by +1.0 over 2 years.

    In plain wordsIn short prepubertal children, conventional GH dosing increased height scores from baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight SDS change with conventional dose
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    40 microg/kg/d · 2 yearsAs given in this study (human).

    Measurements

    Height SDS change
    1 SDS
    conventional

    Source sentences

    Summary
    The changes in HT-SDS were +1.0, +1.1, and +1.6 for conventional, IGF((low)), and IGF((high)), respectively, with IGF((high)) showing significantly greater linear growth response (P < 0.001, compared with the other two groups).
    2 context sentences
    Summary · context
    This was a 2-yr, open-label, randomized, IGF-I concentration-controlled trial.
    Summary · context
    Prepubertal short children [n = 172, mean age 7.53 yr, mean height sd score (HT-SDS) -2.64] with low IGF-I levels (mean IGF-I SDS -3.56) were randomized to receive one of two GH dose-titration arms
  5. 05HumanNon-randomized trialEfficacy outcome

    In short prepubertal children, GH titrated to the low IGF-I target increased height SDS by +1.1 over 2 years.

    In plain wordsIn short prepubertal children, GH titrated to the low IGF-I target increased height scores from baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight SDS change with low IGF-I target
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    Height SDS change
    1.1 SDS
    IGF((low))

    Source sentences

    Summary
    The changes in HT-SDS were +1.0, +1.1, and +1.6 for conventional, IGF((low)), and IGF((high)), respectively, with IGF((high)) showing significantly greater linear growth response (P < 0.001, compared with the other two groups).
    2 context sentences
    Summary · context
    This was a 2-yr, open-label, randomized, IGF-I concentration-controlled trial.
    Summary · context
    Prepubertal short children [n = 172, mean age 7.53 yr, mean height sd score (HT-SDS) -2.64] with low IGF-I levels (mean IGF-I SDS -3.56) were randomized to receive one of two GH dose-titration arms
  6. 06HumanNon-randomized trialEfficacy outcome

    In short prepubertal children, GH titrated to the high IGF-I target increased height SDS by +1.6 over 2 years.

    In plain wordsIn short prepubertal children, GH titrated to the high IGF-I target increased height scores from baseline.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight SDS change with high IGF-I target
    Study

    n: not reported in source

    Analysis
    Primary
    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    Height SDS change
    1.6 SDS
    IGF((high))

    Source sentences

    Summary
    The changes in HT-SDS were +1.0, +1.1, and +1.6 for conventional, IGF((low)), and IGF((high)), respectively, with IGF((high)) showing significantly greater linear growth response (P < 0.001, compared with the other two groups).
    2 context sentences
    Summary · context
    This was a 2-yr, open-label, randomized, IGF-I concentration-controlled trial.
    Summary · context
    Prepubertal short children [n = 172, mean age 7.53 yr, mean height sd score (HT-SDS) -2.64] with low IGF-I levels (mean IGF-I SDS -3.56) were randomized to receive one of two GH dose-titration arms
  7. 07HumanNon-randomized trialEfficacy outcome

    In short prepubertal children receiving GH dose titration, target IGF-I levels were achieved within 6-9 months.

    In plain wordsIn short prepubertal children receiving GH dose titration, target IGF-I levels were achieved within 6-9 months.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableTarget IGF-I attainment
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Measurements

    Time to target IGF-I
    6 to 9 months
    dose-titration arms

    Source sentences

    Summary
    Target IGF-I levels were achieved in the dose-titration arms within 6-9 months.
    2 context sentences
    Summary · context
    This was a 2-yr, open-label, randomized, IGF-I concentration-controlled trial.
    Summary · context
    Prepubertal short children [n = 172, mean age 7.53 yr, mean height sd score (HT-SDS) -2.64] with low IGF-I levels (mean IGF-I SDS -3.56) were randomized to receive one of two GH dose-titration arms
  8. 08HumanObservational studyMechanism

    In short prepubertal children receiving GH, multivariate analyses linked height outcome to IGF-I SDS rise, GH dose, and pretreatment peak-stimulated GH.

    In plain wordsIn short prepubertal children receiving GH, height outcome was linked to IGF-I rise, GH dose, and pretreatment stimulated GH.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableDeterminants of height outcome
    Study

    n: not reported in source

    Outcome group
    Linear growth · Endocrine and hormones
    Studied dose
    Dose not stated · 2 yearsAs given in this study (human).

    Source sentences

    Summary
    Multivariate analyses suggested that the rise in the IGF-I SDS significantly impacted height outcome along with the GH dose and the pretreatment peak-stimulated GH level.
    2 context sentences
    Summary · context
    This was a 2-yr, open-label, randomized, IGF-I concentration-controlled trial.
    Summary · context
    Prepubertal short children [n = 172, mean age 7.53 yr, mean height sd score (HT-SDS) -2.64] with low IGF-I levels (mean IGF-I SDS -3.56) were randomized to receive one of two GH dose-titration arms

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 3NCT00262249

Effect of Growth Hormone in Children With Growth Hormone Deficiency

Novo Nordisk A/Sn = 173Aug 2000 to May 2004

Growth Hormone Disorder · Growth Hormone Deficiency in Children · Growth Disorder · Idiopathic Short Stature

Trial pageClinicalTrials.govUpdated 18 Jan 2017

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.